NEW YORK (Reuters Health), Aug 8 - T cells from colorectal cancer patients can be transduced with a recombinant anticarcinoembryonic antigen (CEA) immunoreceptor so that they become activated by their autologous tumor cells, German researchers report in the August issue of Gut.
Senior investigator Dr. Hinrich Abken told Reuters Health that the results "clearly demonstrate that tolerance of the patient towards his tumor can be overcome by specifically redirecting the patient's own T cells."
Dr. Abken of the University of Cologne and colleagues isolated T cells from colorectal cancer patients and successfully engineered them to express anti-CEA immunoreceptor on the cell surface. In vitro, autologous CEA-positive tumor cells caused the engineered T cells to secrete interferon and lyse the tumor cells.
Furthermore, addition of the intracellular signaling domain CD3zeta plus the CD28 co-stimulator was found to substantially enhance the cellular immune response against autologous tumor cells.
The researchers point out that such in vitro studies "do certainly not reflect in toto the natural tumor microenvironment during T cell attack."
Nevertheless, the approach as well as being promising in treatment may be helpful in prevention, concluded Dr. Abken. "Engineering immunologically competent effector cells, as we have successfully performed ... provides a novel strategy to shape the immune system in order to recognize own tumor cells somewhere in the body and to destroy them before the disease cancer occurs."
By David Douglas
Last Updated: 2006-08-07 13:11:05 -0400 (Reuters Health)
Gut 2006;55:1156-1164.
Related Reading
Mutant DNA fragments detected in plasma of colorectal cancer patients, October 26, 2005
Copyright © 2006 Reuters Limited. All rights reserved. Republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.
![Overview of the study design. (A) The fully automated deep learning framework was developed to estimate body composition (BC) (defined as subcutaneous adipose tissue [SAT] in liters; visceral adipose tissue [VAT] in liters; skeletal muscle [SM] in liters; SM fat fraction [SMFF] as a percentage; and intramuscular adipose tissue [IMAT] in deciliters) from MRI. The fully automated framework comprised one model (model 1) to quantify different BC measures (SAT, VAT, SM, SMFF, and IMAT) as three-dimensional (3D) measures from whole-body MRI scans. The second model (model 2) was trained to identify standardized anatomic landmarks along the craniocaudal body axis (z coordinate field), which allowed for subdividing the whole-body measures into different subregions typically examined on clinical routine MRI scans (chest, abdomen, and pelvis). (B) BC was quantified from whole-body MRI in over 66,000 individuals from two large population-based cohort studies, the UK Biobank (UKB) (36,317 individuals) and the German National Cohort (NAKO) (30,291 individuals). Bar graphs show age distribution by sex and cohort. BMI = body mass index. (C) After the performance assessment of the fully automated framework, the change in BC measures, distributions, and profiles across age decades were investigated. Age-, sex-, and height-adjusted body composition reference curves were calculated and made publicly available in a web-based z-score calculator (https://circ-ml.github.io).](https://img.auntminnieeurope.com/mindful/smg/workspaces/default/uploads/2026/05/body-comp.XgAjTfPj1W.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
